Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Genetic Variant Could Dictate Rituximab Response in Lupus

Publish date:: July 29, 2019

Key clinical point: Genetic polymorphism in the Fc gamma receptor IIIA (FCGR3A) gene with increased affinity for rituximab might determine response to drug in systemic lupus erythematosus (SLE).

Major finding: A higher percentage of patients achieved a BILAG major clinical response if they had the FCGR3A-158V allele, compared with the low affinity 158 FF genotype (48% vs. 23%).

Study details: An observational, prospective, single-center, longitudinal cohort study involving 85 SLE patients who were treated with rituximab.

Disclosures: The U.K. National Institute for Health Research funded the study. Dr. Md Yusof had no conflicts of interest to disclose; some coauthors disclosed ties to Roche, GlaxoSmithKline, and AstraZeneca, among other companies.

Citation:

Md Yusof MY et al. Ann Rheum Dis. Jun 2019;78(Suppl 2):1069-70. Abstract SAT0009, doi: 10.1136/annrheumdis-2019-eular.6919.

This Week's Must Reads

Osteoporosis prevalence in PsA similar to general population,

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

Weight loss may be paramount lifestyle change in preventing gout,

Gut microbiome influences response to methotrexate in new-onset RA patients,

Early treatment of RA with DMARDs promotes sustained remission,

Must Reads in Lupus & Connective Tissue Diseases

High-need, high-cost lupus patients described for first time,

Slow taper off antimalarial is best to avoid lupus flare during remission,

Sjögren’s symptom clusters may identify treatment options,

Transcutaneous VNS on the ear shows positive effects in lupus pilot trial,

ASSET extension supports abatacept as treatment for diffuse cutaneous systemic sclerosis,